Zapping the brain to understand emotions: a first step
NCT ID NCT06607432
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new device called transcranial interference stimulation (tIS) in 10 healthy adults. The goal is to see if it is safe and can change brain activity related to recognizing emotions in faces. If it works, this approach might one day help people with conditions like schizophrenia.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Transcranial Interference Stimulation (tIS) - a device that uses weak electrical fields to stimulate deep brain areas
- What this could lead to
- If successful, this could pave the way for future studies using tIS to treat social and emotional problems in disorders like schizophrenia.
- What could go wrong
- This is a very early, small safety study in only 10 healthy people. It is not designed to test effectiveness, and many such early studies do not lead to treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY CONTROLS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Columbia University Irving Medical Center/NewYork-Presbyterian Hospital (CUIMC/NYPH)
RECRUITINGNew York, New York, 10032, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Mining mountains of data to outsmart diabetes complications
- Psilocybin without the trip: scientists hunt for a microdose that skips hallucinations
- Manitoba DNA hunt could revolutionize schizophrenia care
- Brain insulin study aims to uncover why antipsychotics cause weight gain
- Ketone drink may boost brain fuel in prediabetes
- Experimental drug VVZ-2471 gets first safety check in humans